Last reviewed · How we verify
Very low nicotine cigarettes
At a glance
| Generic name | Very low nicotine cigarettes |
|---|---|
| Sponsor | Rutgers University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Infections and infestations
- Respiratory, thoracic, and mediastinal disorders
- Gastrointestinal disorders
- General disorders
- Nervous system disorders
- Musculoskeletal and connective tissue disorders
- Cough
- Elevated CES-D score
- Nasal congestion/Rhinorrhea
- Headache/Migraine
- OASIS Score Increase
- Vascular disorders
Key clinical trials
- Effects of a Low Nicotine Standard and Tobacco Prices on Illegal Cigarette Purchasing (NA)
- Opioids, Low Nicotine Cigarettes, and Chronic Pain (NA)
- Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration (PHASE2)
- Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers (NA)
- Project 4, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Pregnant Women (PHASE1, PHASE2)
- Communicating About Nicotine Reduction in Cigarettes (NA)
- Cardiovascular Effects of Very Low Nicotine Content Cigarettes (EARLY_PHASE1)
- Low Nicotine Cigarettes Plus Electronic Cigarettes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Very low nicotine cigarettes CI brief — competitive landscape report
- Very low nicotine cigarettes updates RSS · CI watch RSS
- Rutgers University portfolio CI